Engineered immune cells join forces with targeted drug to fight Hard-to-Treat breast cancer

NCT ID NCT07553390

Not yet recruiting Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a new combination treatment for people with advanced breast cancer that has not responded to standard therapies. The treatment uses specially engineered immune cells (TRICK-NK) plus a targeted drug called T-Dxd. The study aims to find the safest dose and see if the combination can help control the disease. About 60 participants will be enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: engineered immune cells (TRICK-NK) and trastuzumab deruxtecan (T-Dxd)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced breast cancer that has stopped responding to standard therapies.
What could go wrong: This is a very early Phase 1 trial with only 60 participants, so it is primarily testing safety and dosing. The combination may not control the disease, and side effects could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

UT MD Anderson

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.